Patent · US Active

Selective inhibition of polyglutamine protein expression

US9340785B2 · kind B2 · utility

8Cited by
12References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 3, 2014
Grant dateMay 17, 2016
Priority date—
Expiry dateNov 3, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/3231
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntington using nucleic acid analogs. Peptide nucleic acids and locked nucleic acids are particularly useful analogs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.